Puerarin induces hepatocellular carcinoma cell apoptosis modulated by mapk signaling pathways in a dose-dependent manner

Anticancer Research

Volumn 37, Issue 8, 2017, Pages 4425-4431

  Zhang, Wei Guo ^a   Yin, Xiu Cai ^b   Liu, Xiao Fang ^a   Meng, Ke Wei ^a   Tang, Kun ^a   Huang, Fei Long ^a   Xu, Gang ^a   Gao, Jie ^a  

^a YANTAI YUHUANGDING HOSPITAL   (China)

^b Rongcheng Shidao Peoples Hospital   (China)

Author keywords

Apoptosis; Hepatocellular carcinoma (HCC); MAPK pathway; Puerarin

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PUERARIN; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; ISOFLAVONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CELL VIABILITY; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LIVER CELL CARCINOMA; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; MAPK SIGNALING; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOFLAVONES; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES;

EID: 85026198441     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11837     Document Type: Conference Paper

References (31)

1. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2013.
2. Roberts LR: Sorafenib in liver cancer-Just the beginning. N Engl J Med 359: 420-422, 2008.
3. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
4. Ryu SH and Chung YH: How to overcome multidrug resistance in chemotherapy for advanced hepatocellular carcinoma. Liver Int 30: 496-498, 2010.
5. Gu W, Fang FF, Li B, Cheng BB and Ling CQ: Characterization and resistance mechanisms of a 5-fluorouracil-resistant hepatocellular carcinoma cell line. Asian Pac J Cancer Prev 13(9): 4807-4814, 2012.
6. Tian F, Xu LH, Zhao W, Tian LJ and Ji XL: The neuroprotective mechanism of puerarin treatment of acute spinal cord injury in rats. Neurosci Lett 543: 64-68, 2013.
7. Michihara S, Tanaka T, Uzawa Y, Moriyama T and Kawamura Y: Puerarin exerted anti-osteoporotic action independent of estrogen receptor-mediated pathway. J Nutr Sci Vitaminol Tokyo 58(3): 202-209, 2012.
8. Wolfe K, Wu X and Liu RH: Antioxidant activity of apple peels. J Agric Food Chem 51: 609-614, 2003.
9. Arao T, Udayama M, Kinjo J, Nohara T, Funakoshi T and Kojima S: Preventive effects of saponins from Puerariae radix (the root of Pueraria lobata Ohwi) on in vitro immunological injury of rat primary hepatocyte cultures. Biol Pharm Bull 20: 988-991, 1997.
10. Wang HK, Xia Y, Yang ZY, Natschke SL and Lee KH: Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents. Adv Exp Med Biol 439: 191-225, 1998.
11. Theoharides TC, Alexandrakis M, Kempuraj D and Lytinas M: Anti-inflammatory actions of flavonoids and structural requirements for new design. Int J Immunopathol Pharmacol 14: 119-127, 2001.
12. Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S, Lal B and Sharma S: In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther 6: 918-925, 2007.
13. Yu Z and Li W: Induction of apoptosis by peurarin in colon cancer HT-29 cells. Cancer Lett 238: 53-60, 2006.
14. Zeng YP, Yang ZR, Guo XF, Jun W and Dong WG: Synergistic effect of puerarin and 5-fluorouracil on hepatocellular carcinoma. Oncol Lett 8(6): 2436-2442, 2014.
15. Wang Y, Ma Y, Zheng Y, Song J, Yang X, Bi C, Zhang D and Zhang Q: In vitro and in vivo anticancer activity of a novel puerarin nanosuspension against colon cancer, with high efficacy and low toxicity. Int J Pharm 441(1-2): 728-735, 2013.
16. Lin YJ, Hou YC, Lin CH, Hsu YA, Sheu JJ, Lai CH, Chen BH, Lee Chao PD, Wan L and Tsai FJ: Puerariae radix isoflavones and their metabolites inhibit growth and induce apoptosis in breast cancer cells. Biochem Biophys Res Commun 378(4): 683-688, 2009.
17. Hien TT, Kim HG, Han EH, Kang KW and Jeong HG: Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-kappaB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells. Mol Nutr Food Res 54(7): 918-928, 2010.
18. Zhu G, Wang X, Wu S and Li Q: Involvement of activation of PI3K/Akt pathway in the protective effects of puerarin against MPP+-induced human neuroblastoma SH-SY5Y cell death. Neurochem Int 60: 400-408, 2012.
19. Zhou YX, Zhang H, Peng C. Puerarin: A Review of pharmacological effects. Phytother Res 28(7): 961-975, 2014.
20. Wang PP, Zhu XF, Yang L, Liang H, Feng SW and Zhang RH: Puerarin stimulates osteoblasts differentiation and bone formation through estrogen receptor, p38 MAPK, and Wnt/?-catenin pathways. J Asian Nat Prod Res 14(9): 897-905, 2012.
21. Liu LJ, Liu LQ, Bo T, Li SJ, Zhu Z, Cui RR and Mao DA: Puerarin suppress apoptosis of human osteoblasts via ERK signaling pathway. Int J Endocrinol 2013: 786574, 2013.
22. Zhu G, Wang X, Chen Y, Yang S, Cheng H, Wang N and Li Q: Puerarin protects dopaminergic neurons against 6-hydroxydopamine neurotoxicity via inhibiting apoptosis and upregulating glial cell line-derived neurotrophic factor in a rat model of Parkinson's disease. Planta Med 76: 1820-1826, 2010.
23. Zhang H, Liu Y, Lao M, Ma Z and Yi X: Puerarin protects Alzheimer's disease neuronal cybrids from oxidant-stress induced apoptosis by inhibiting pro-death signaling pathways. Exp Gerontol 46: 30-37, 2011.
24. Wada T and Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23(16): 2838-2849, 2004.
25. Dangle PP, Zaharieva B, Jia H and Pohar KS: Ras-mapk pathway as a therapeutic target in cancer-Emphasis on bladder cancer. Recent Pat Anticancer Drug Discov 4: 125-136, 2009.
26. Liu J, Wu N, Ma LN, Zhong JT, Liu G, Zheng LH and Lin XK: p38 MAPK signaling mediates mitochondrial apoptosis in cancer cells induced by oleanolic acid. Asian Pac J Cancer Prev 15(11): 4519-4525, 2014.
27. Li Yuan, Jing Wang, Haifang Xiao, Wanqiang Wu, Yutang Wang and Xuebo Liu: MAPK signaling pathways regulate mitochondrial-mediated apoptosis induced by isoorientin in human hepatoblastoma cancer cells. Food Chem Toxicol 53: 62-68, 2013.
28. Xu X, Wang J, Zhang H, Tian G and Liu Y: Puerarin reduces apoptosis in rat hippocampal neurons culture in high glucose medium by modulating the p38 mitogen activated protein kinase and c-Jun N-terminal kinase signaling pathways. J Tradit Chin Med 36(1): 78-84, 2016.
29. Guardavaccaro D and Clevers H: Wnt/beta-catenin and mapk signaling: Allies and enemies in different battlefields. Sci Signal 5(219): pe15, 2012.
30. Zhang Y, Pizzute T and Pei M: A review of crosstalk between mapk and wnt signals and its impact on cartilage regeneration. Cell Tissue Res 358: 633-649, 2014.
31. Wang L, Li J, Zhao H, Hu J, Ping Y, Li F, Lan Y, Xu C, Xiao Y and Li X: Identifying the crosstalk of dysfunctional pathways mediated by lncRNAs in breast cancer subtypes. Mol Biosyst 12(3): 711-720, 2016.